Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2024-12-16 DOI:10.1016/j.cllc.2024.12.005

Timothy Schieber, Prakash Neupane, Haoran Li, Chao Huang, Jun Zhang

引用次数: 0

Abstract

•
Tarlatamab's onset of tumor regression can be as short as 2 weeks.
•
Rechallenging tarlatamab after grade 3 CRS with standard premedication is safe.
•
Tarlatamab combined with IMRT offers safe and highly effective CNS control.
•
A collapsed lung from tumor burden may re-expand with tarlatamab monotherapy.

查看原文本刊更多论文

3级细胞因子释放综合征导致肿瘤在两周内消退和萎陷肺重开后再用塔拉他单抗：一例报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.